ALPN - Alpine Immune Sciences Is A Blind Buy After The Recent Price Decrease

• The strategic agreement with AbbVie for the development of ALPN-101 is the most valuable asset of the company.
• The recent share price decline can be attributed to several factors, including the expected announcement of ALPN-101 Phase 2 trail initiation and the associated AbbVie agreement milestone.
• General market movement and the recent absence of ALPN-101 in AACR virtual conference may have contributed to this price action.
• We believe that at the present price the company is a buying opportunity for short-term price appreciation.

For further details see: